Uncategorized

Russia’s Biosimilar Powerhouse: BIOCAD’s Patent Pipeline and the Oncology Disruption No One in the West Is Watching

Russia’s biosimilar story is no longer a side plot—it’s becoming the plot.
If you’ve been watching the West’s oncology pipeline and pricing debates, you may have missed the quieter shift happening in Moscow: a growing biosimilar powerhouse building a p…

Russia’s Biosimilar Powerhouse: BIOCAD’s Patent Pipeline and the Oncology Disruption No One in the West Is Watching Read Post »

Uncategorized

Read the Drug Patent Clock Before the Market Does: A step-by-step technical guide to forecasting pharmaceutical drug patent expiry for IP teams, R&D strategists, and institutional investors

The drug patent clock is ticking—most IP teams are forecasting it blind.
In pharma, timing isn’t just strategy—it’s survival. A single missed milestone can mean a late challenge, a mispriced pipeline, or an R&D roadmap built on assumptions that the…

Read the Drug Patent Clock Before the Market Does: A step-by-step technical guide to forecasting pharmaceutical drug patent expiry for IP teams, R&D strategists, and institutional investors Read Post »

Uncategorized

Drug Market Entry Intelligence: The Definitive Guide for Pharma Strategists, IP Teams, and Institutional Investors

Pharma strategy is often built on what’s known—pipeline charts, trial readouts, formulary wins. But the real competitive edge is increasingly about what’s about to become knowable: when exclusivity ends, when generics can launch, when “authorized” path…

Drug Market Entry Intelligence: The Definitive Guide for Pharma Strategists, IP Teams, and Institutional Investors Read Post »

Biotechblog
Scroll to Top